WO2024141790 - GENETICALLY MODIFIED CELLS COMPRISING A NUCLEIC ACID ENCODING A CD40L BINDING AGENT AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2024/141790
Publication Date
04.07.2024
International Application No.
PCT/IB2023/000797
International Filing Date
29.12.2023
Title **
[English]
GENETICALLY MODIFIED CELLS COMPRISING A NUCLEIC ACID ENCODING A CD40L BINDING AGENT AND USES THEREOF
[French]
CELLULES GÉNÉTIQUEMENT MODIFIÉES COMPRENANT UN ACIDE NUCLÉIQUE CODANT POUR UN AGENT DE LIAISON CD40L ET LEURS UTILISATIONS
Applicants **
AFFYXELL THERAPEUTICS CO., LTD.
#209, 88 Somang-gil, Juchon-myeon
Gimhae-si
Gyeongsangnam-do
50969, KR
Inventors
ANH, Kyong-Hoon
Techno Park Unit No. 404 80-59
Golden root-ro Juchon-myeon
Gimhae-Si
50969, KR
CHOI, Sung Hyun
Techno Park Unit No. 404 80-59
Golden root-ro Juchon-myeon
Gimhae-Si
50969, KR
KIM, Kinam
Techno Park Unit No. 404 80-59
Golden root-ro Juchon-myeon
Gimhae-Si
50969, KR
RYU, Jong Sang
Techno Park Unit No. 404 80-59
Golden root-ro Juchon-myeon
Gimhae-Si
50969, KR
JEON, Sengho
Techno Park Unit No. 404 80-59
Golden root-ro Juchon-myeon
Gimhae-Si
50969, KR
Priority Data
10-2022-0188961
29.12.2022
KR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
MOIP
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 4476 | |
| EPO | Filing, Examination | 38948 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 19310 |
Total: 63898 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Disclosed are a genetically modified cell in which a nucleic acid encoding a CD40L binding agent (e.g., a stefin A protein variant specifically binding to CD40L or a fusion protein including the same ) is introduced into a host cell and uses thereof. Provided are genetically modified cells expressing a CD40L binding agent enabling secretion thereof, expression thereof on a cell membrane, and/or intracellular localization thereof, and are thereby capable of reducing or inhibiting the activity of CD40L. Provided genetically modified cells may inhibit T-cell activity and B-cell activity and exhibit an immunosuppressive effect, and may be thus useful for the prevention or treatment of immune diseases such as autoimmune diseases or inflammatory diseases.[French]
Est divulguée une cellule génétiquement modifiée dans laquelle un acide nucléique codant pour un agent de liaison CD40L (par exemple, un variant de protéine se liant spécifiquement à CD40L ou une protéine de fusion le comprenant) est introduit dans une cellule hôte et ses utilisations. L'invention propose des cellules génétiquement modifiées exprimant un agent de liaison à CD40L permettant leur sécrétion, leur expression sur une membrane cellulaire, et/ou leur localisation intracellulaire, et pouvant ainsi réduire ou inhiber l'activité de CD40L. L'invention propose des cellules génétiquement modifiées pouvant inhiber l'activité des cellules T et l'activité des cellules B et présentant un effet immunosuppresseur, et pouvant ainsi être utiles pour la prévention ou le traitement de maladies immunitaires telles que des maladies auto-immunes ou des maladies inflammatoires.